Diabetes Tipo II

Referencias bibliográficas:

1 NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4・4 million participants. Lancet 2016; 387: 1513–30.

2 GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990– 2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1545–602.

3 Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics 2015; 33: 811–31.

4 WHO. Non-communicable diseases country profi le 2014. July, 2014. http://www.who.int/nmh/publications/ncd-profi les-2014/en/ (accessed Oct 6, 2016).

5 Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–93.

6 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.

7 ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–72.

8 Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129–39.

9 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–89.

10 Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014; 383: 2008–17.

11 Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009; 32: 187–92.

12 Cefalu WT. Glycemic targets and cardiovascular disease. N Engl J Med 2008; 358: 2633–35.

13 Elwen FR, Huskinson A, Clapham L, et al. An observational study of patient characteristics and mortality following hypoglycemia in the community. BMJ Open Diabetes Res Care 2015; 3: e000094.

14 Tricco AC, Ivers NM, Grimshaw JM, et al. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet 2012; 379: 2252–61.

15 International Diabetes Federation. IDF Diabetes Atlas, 7th edn. 2015. http://www.diabetesatlas.org/ (accessed Oct 6, 2016).

16 Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.

17 Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med 2015; 373: 1720–32.

18 The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215–22.

19 Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992; 15: 815–19.

20 Grarup N, Sandholt CH, Hansen T, Pedersen O.Genetic susceptibility to type 2 diabetes and obesity: from genome-wide association studies to rare variants and beyond.

Diabetologia 2014; 57: 1528–41.

21 Jenkinson CP, Goring HH, Arya R, Blangero J, Duggirala R,DeFronzo RA. Transcriptomics in type 2 diabetes: Bridging the gap between genotype and phenotype. Genom Data 2015; 8: 25–36.

22 Leong A, Porneala B, Dupuis J, Florez JC, Meigs JB. Type 2 diabetes genetic predisposition, obesity, all-cause mortality risk in the US: a multiethnic analysis. Diabetes Care 2016; 39: 539–46.

23 Oram RA, Patel K, Hill A, et al. A type 1 diabetes genetic risk score can aid discrimination between type 1 and type 2 diabetes in young adults. Diabetes Care 2016; 39: 337–44.

24 Constantino MI, Molyneaux L, Limacher-Gisler F, et al. Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care 2013; 36: 3863–69.

25 Wong ND, Zhao Y, Patel R, et al. Cardiovascular risk factor targets and cardiovascular disease event risk in diabetes: a pooling project of the Atherosclerosis Risk in Communities Study, Multi-ethnic Study of Atherosclerosis, and Jackson Heart Study. Diabetes Care 2016; 39: 668–76.

26 TODAY Study Group, Zeitler P, Hirst K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012; 366: 2247–56.

27 Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773–95.

28 Schwartz SS, Epstein S, Corkey BE, Grant SF, Gavin JR 3rd, Aguilar RB. The time is right for a new classifi cation system for diabetes: rationale and implications of the β-Cell-Centric Classifi cation Schema. Diabetes Care 2016; 39: 179–86.

29 Gruber K. Moving towards a more precise treatment of diabetes. Lancet Diabetes Endocrinol 2015; 3: 171.

30 de Jager J, Kooy A, Schalkwijk C, et al. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. J Intern Med 2014; 275: 59–70.

31 Ceriello A, Esposito K, Testa R, Bonfi gli AR, Marra M, Giugliano D. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an “endothelial resistance” to glucagon-like peptide 1 in diabetes. Diabetes Care 2011; 34: 697–702.

32 Wilding JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic signifi cance through sodium glucose co-transporter 2 inhibitors. Metabolism 2014; 63: 1228–37.

33 Orozco LJ, Buchleitner AM, Gimenez-Perez G, Roque I Figuls M, Richter B, Mauricio D. Exercise or exercise and diet for preventing type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; 3: CD003054.

34 Merlotti C, Morabito A, Pontiroli AE. Prevention of type 2 diabetes; a systematic review and meta-analysis of diff erent intervention strategies. Diabetes Obes Metab 2014; 16: 719–27.

35 Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol 2015; 3: 866–75.

36 Perreault L, Temprosa M, Mather KJ, et al. Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study. Diabetes Care 2014; 37: 2622–31.

37 Cardona-Morrell M, Rychetnik L, Morrell SL, Espinel PT, Bauman A. Reduction of diabetes risk in routine clinical practice: are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and

meta-analysis. BMC Public Health 2010; 10: 653.

38 Dunkley AJ, Bodicoat DH, Greaves  CJ, et al. Diabetes prevention in the real world: eff ectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis. Diabetes Care 2014; 37: 922–33.

39 Maruthappu M, Sood H, Keogh B. Radically upgrading diabetes prevention in England. Lancet Diabetes Endocrinol 2015; 3: 312–13.

40 Webb DR, Gray LJ, Khunti K, et al. Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifi es modifi able cardiovascular risk: the ADDITION-Leicester study. Diabetologia 2011; 54: 2237–46.

41 Simmons RK, Echouff o-Tcheugui JB, Sharp SJ, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 2012; 380: 1741–48.

42 Khunti K, Mani H, Achana F, Cooper N, Gray LJ, Davies MJ. Systematic review and meta-analysis of response rates and diagnostic yield of screening for type 2 diabetes and those at high risk of diabetes. PLoS One 2015; 10: e0135702.

43 Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K, DETECT-2 Collaboration Writing Group. Glycemic thresholds for diabetes-specifi c retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care 2011; 34: 145–50.

44 Welsh KJ, Kirkman MS, Sacks DB. Role of glycated proteins in the diagnosis and management of diabetes: research gaps and future directions. Diabetes Care 2016; 39: 1299–306.

45 Thanabalasingham G, Pal A, Selwood MP, et al. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young. Diabetes Care 2012; 35: 1206–12.

46 Norris SL, Zhang X, Avenell A, et al. Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev 2005; 2: CD004095.

47 Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006; 3: CD002968.

48 Davies MJ, Heller S, Skinner TC, et al. Eff ectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ 2008; 336: 491–95.

49 Khunti K, Gray LJ, Skinner T, et al. Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care. BMJ 2012; 344: e2333.

50 Belalcazar LM, Reboussin DM, Haff ner SM, et al. A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifi es metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care 2010; 33: 2297–303.

51 Look AHEAD Research Group, Wing RR, Bolin P, et al. Cardiovascular eff ects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369: 145–54.

52 Wing RR, Bond DS, Gendrano IN 3rd, et al. Effect of intensive lifestyle intervention on sexual dysfunction in women with type 2 diabetes: results from an ancillary Look AHEAD study. Diabetes Care 2013; 36: 2937–44.

53 Rubin RR, Wadden TA, Bahnson JL, et al. Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD Trial. Diabetes Care 2014; 37: 1544–53.

54 Look AHEAD Research Group. Eff ect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2014; 2: 801–09.

55 Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–44.

56 Fox CS, Golden SH, Anderson C, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientifi c statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2015; 38: 1777–803.

57 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65.

58 Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Eff ects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–59.

59 Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617–22.

60 Zinman B, Wanner C, Lachin JM, et al. Empaglifl ozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 74: 1094.

61 Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311–22.

62 Control Group, Turnbull FM, Abraira C, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288–98.

63 Ray KK, Seshasai SR, Wijesuriya S, et al. Eff ect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765–72.

64 Riddle MC, Ambrosius WT, Brillon DJ, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3・4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010; 33: 983–90.

65 Wong MG, Perkovic V, Chalmers J, et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 2016; 39: 694–700.

66 Nissen SE, Wolski K. Eff ect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–71.

67 Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317–26.

68 White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327–35.

69 US Food and Drug Administration. Diabetes medications containing saxagliptin and alogliptin: drug safety communication—risk of heart failure. April 19, 2016. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm (accessed Oct 6, 2016).

70 Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232–42.

71 Sarafi dis PA, Tsapas A. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2016; 374: 1092.

72 AstraZeneca. Multicenter trial to investigate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58). 2015. https://clinicaltrials.gov/ct2/show/

NCT01730534 (accessed Oct 21, 2015).

73 Janssen Research and Development LLC. CANVAS—CANagliflozin cardioVascular Assessment Study. 2015. https://clinicaltrials.gov/ct2/show/NCT01032629 (accessed Oct 21, 2015).

74 Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; published online Sept 15. DOI:10.1056/NEJMoa1607141.